CatherineMargaretKellyMD

PubMed

• 34 citations
  Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer
  Libero Santarpia, Giulia Bottai, Catherine M. Kelly, Balázs Győrffy, Borbála Székely, Lajos Pusztai> ;The Oncologist. 2016 Sep 1
• 10 citations
  Efficacy and safety of vismodegib: a new therapeutic agent in the treatment of basal cell carcinoma
  Tomas G. Lyons, Grainne M. O'Kane, Catherine M. Kelly> ;Expert Opinion on Drug Safety. 2014 Jul 17
• 24 citations
  Vemurafenib for the treatment of melanoma
  Emmet Jordan, Catherine M. Kelly> ;Expert Opinion on Pharmacotherapy. 2012 Nov 10
• 32 citations
  Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer
  Anna M. Sawka, Sharon E. Straus, Lorne Rotstein, James D. Brierley, Richard W. Tsang, Sylvia L. Asa, Phillip Segal, Catherine M. Kelly, Afshan Zahedi, Jeremy L. Freema...> ;Journal of Clinical Oncology. 2012 Jul 2
• 6 citations
  Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer
  Geraldine O'Sullivan Coyne, Janice Walsh, Catherine M. Kelly> ;Expert Opinion on Drug Safety. 2012 Jun 23
• 5 citations
  Personalized Medicine: What Exactly Is It and Can We Truly Measure It?
  Catherine M. Kelly, Kathleen I. Pritchard> ;Journal of Clinical Oncology. 2012 May 14
• 53 citations
  Agreement in Risk Prediction Between the 21-Gene Recurrence Score Assay (Oncotype DX®) and the PAM50 Breast Cancer Intrinsic Classifier™ in Early-Stage Estrogen Recept...
  Catherine M. Kelly, Philip S. Bernard, Savitri Krishnamurthy, Bailiang Wang, Mark T. W. Ebbert, Roy R. L. Bastien, Kenneth M. Boucher, Elliana Young, Takayuki Iwamoto,...> ;The Oncologist. 2012 Apr 1
• Aromatase inhibitors in premenopausal breast cancer
  Catherine M. Kelly, Aman U. Buzdar> ;The Lancet. Oncology. 2012 Apr 1
• 31 citations
  Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer
  Catherine M. Kelly, Marjorie C. Green, Kristine Broglio, Eva Thomas, Abenaa M. Brewster, Vicente Valero, Nuhad K. Ibrahim, Ana M. Gonzalez-Angulo, Daniel J. Booser, Ro...> ;Journal of Clinical Oncology. 2012 Mar 20
• Capecitabine in operable triple receptor-negative breast cancer: A subgroup analysis of a randomized phase III trial.
  Kelly CM, Green MC, Broglio K, Pusztai L, Thomas E, Brewster A, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Hunt K, Hortobagyi GN, Buzdar A> ;J. Clin. Oncol.. 2011-09-20
• 77 citations
  Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
  Catherine M. Kelly, Savitri Krishnamurthy, Giampaolo Bianchini, Jennifer K. Litton, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Lajos Pusztai> ;Cancer. 2010 Nov 15
• 9 citations
  Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?
  Catherine M. Kelly, Gabriel N. Hortobagyi> ;Surgical Oncology Clinics of North America. 2010 Jul 1
• 91 citations
  Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
  Daphne Tsoi, Miho Inoue, Catherine M. Kelly, Sunil Verma, Kathleen I. Pritchard> ;The Oncologist. 2010 May 1
• 13 citations
  Review of the Clinical Studies Using the 21-Gene Assay
  Catherine M. Kelly, Ellen Warner, Daphne Tsoi, Sunil Verma, Kathleen I. Pritchard> ;The Oncologist. 2010 May 1
• 11 citations
  Disseminated Tumor Embolism From Breast Cancer Leading to Multiorgan Failure
  Daphne Tsoi, Corwyn Rowsell, Caitlin McGregor, Catherine M. Kelly, Sunil Verma, Kathleen I. Pritchard> ;Journal of Clinical Oncology. 2010 Apr 20
• A lifetime cancer bioassay of quinacrine administered into the uterine horns of female rats.
  Cancel, A.M., Dillberger, J.E., Kelly, C.M., Bolte, H.F., Creasy, D.M., Sokal, D.C.> ;Regul Toxicol Pharmacol. 2010-03-01
• 285 citations
  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
  Catherine M. Kelly, David N. Juurlink, Tara Gomes, M. Duong-Hua, Kathleen I. Pritchard, Peter C. Austin, Lawrence Paszat> ;BMJ. 2010 Feb 9
• 3 citations
  Aromatase inhibitors alone or in sequence with tamoxifen - Clinical Evaluation of the BIG 1-98 trial
  Catherine M. Kelly, Aman U. Buzdar> ;Expert Opinion on Pharmacotherapy. 2010 Jan 27
• Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.
  Pusztai, L., Viale, G., Kelly, C.M., Hudis, C.A.> ;Oncologist. 2010
• Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer.
  Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard K> ;J. Clin. Oncol.. 2009-05-20
• The effect of food on the single dose pharmacokinetics of cediranib.
  Jayson GC, Evans TR, Harris A, Mitchell CL, Kelly C, Middleton M, Fielding A, Laud P, Robertson J, Puchalski TA> ;J. Clin. Oncol.. 2008-05-20
• Systematic validation of novel breast cancer progression-associated biomarkers via high-throughput antibody generation and application of tissue microarray technology:...
  Kelly CM, Penny S, Brennan D, O'Brien S, Fagan A, Culhane AC, Jirstrom K, Ponten F, Uhlen M, Gallagher WM> ;J. Clin. Oncol.. 2008-05-20
• Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): Frequency and characterization in clinical practice.
  Presant CA, Kelly C, Bosserman L, Upadhyaya G, Vakil M, Horns R, Ebrahimi B, Yeon C, Howard F, Rios A> ;J. Clin. Oncol.. 2006-06-20
• 16 citations
  Epidermal growth factor receptor-targeted agents for lung cancer.
  Petra Martin, Catherine M. Kelly, Desmond N. Carney> ;Cancer Control. 2006 Apr 1
• Intensity modulated radiation therapy (IMRT) may reduce the oesophageal toxicity of hypofractionated accelerated 3-D radiation for non small cell lung carcinoma.
  Thirion P, Kelly C, O' Shea C, Collins C, Holmberg O, Michael M, Pomeroy M, Hollywood D, Faul C, Armstrong J> ;J. Clin. Oncol.. 2004-07-15
• Join now to see all